Cristina Magi-Galluzzi
Overview
Explore the profile of Cristina Magi-Galluzzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
233
Citations
6390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michalova K, Martinek P, Mezencev R, Gupta S, Williamson S, Wasco M, et al.
Am J Surg Pathol
. 2024 Dec;
49(3):217-226.
PMID: 39726250
Juxtaglomerular cell tumor (JxGCT) is a rare type of renal neoplasm demonstrating morphologic overlap with some mesenchymal tumors such as glomus tumor (GT) and solitary fibrous tumor (SFT). Its oncogenic...
2.
Lobo A, Collins K, Kaushal S, Acosta A, Akgul M, Adhya A, et al.
Histopathology
. 2024 Jul;
85(5):748-759.
PMID: 39075659
Aims: Urothelial carcinoma (UC) demonstrates significant molecular and histologic heterogeneity. The WHO 2022 classification has hinted at adding molecular signatures to the morphologic diagnosis. As morphology and associated molecular repertoire...
3.
Hiremath A, Corredor G, Li L, Leo P, Magi-Galluzzi C, Elliott R, et al.
Heliyon
. 2024 Apr;
10(8):e29602.
PMID: 38665576
Objectives: To evaluate the added benefit of integrating features from pre-treatment MRI (radiomics) and digitized post-surgical pathology slides (pathomics) in prostate cancer (PCa) patients for prognosticating outcomes post radical-prostatectomy (RP)...
4.
Lobo J, Canete-Portillo S, Pena M, McKenney J, Aron M, Massicano F, et al.
Mod Pathol
. 2024 Apr;
37(6):100492.
PMID: 38614322
Juxtaglomerular cell tumor (JGCT) is a rare neoplasm, part of the family of mesenchymal tumors of the kidney. Although the pathophysiological and clinical correlates of JGCT are well known, as...
5.
Shah R, Magi-Galluzzi C
Adv Anat Pathol
. 2023 Dec;
31(2):59-60.
PMID: 38158731
No abstract available.
6.
Lobo J, Tenace N, Canete-Portillo S, Carneiro I, Henrique R, Luciano R, et al.
Histopathology
. 2023 Nov;
84(3):507-514.
PMID: 37965687
Aims: The distinction of high-grade prostate cancer (PCa) from poorly differentiated urothelial carcinoma (UC) can be somewhat challenging on clinical and morphological grounds alone, yet it is of great importance...
7.
Lobo J, Harik L, Peyton C, Morini M, Zein-Sabatto B, Winokur T, et al.
Virchows Arch
. 2023 Nov;
484(4):697-702.
PMID: 37957341
Solitary fibrous tumour (SFT) is a mesenchymal neoplasm with variable behaviour, very rarely involving the genitourinary (GU) tract. Most reported cases correspond to isolated case reports. STAT6 immunohistochemistry is a...
8.
Rawat C, Ben-Salem S, Singh N, Chauhan G, Rabljenovic A, Vaghela V, et al.
Cancer Res
. 2023 Oct;
83(24):4142-4160.
PMID: 37801613
Significance: The poorly characterized protein kinase citron kinase is a therapeutic target in prostate cancer that drives tumor growth by regulating diverse substrates, which control several hallmarks of aggressive prostate...
9.
Li L, Shiradkar R, Gottlieb N, Buzzy C, Hiremath A, Viswanathan V, et al.
Med Phys
. 2023 Sep;
51(4):2549-2562.
PMID: 37742344
Background: Accurate delineations of regions of interest (ROIs) on multi-parametric magnetic resonance imaging (mpMRI) are crucial for development of automated, machine learning-based prostate cancer (PCa) detection and segmentation models. However,...
10.
Li L, Shiradkar R, Tirumani S, Bittencourt L, Fu P, Mahran A, et al.
Eur J Radiol Open
. 2023 Jul;
10:100496.
PMID: 37396490
Background: around one third of clinically significant prostate cancer (CsPCa) foci are reported to be MRI non-visible (MRI─). Objective: To quantify the differences between MR visible (MRI+) and MRI CsPCa...